HOME >> BIOLOGY >> NEWS
After 2 years, study shows Revlimid patients live longer and remain transfusion free

Orlando, FL (December 11, 2006) -- Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, presented the final results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) at this years American Society of Hematology (ASH) meeting. This breakthrough data showed that in MDS patients with chromosome 5q deletion treatment with Revlimid can provide long-term durable results and help them to achieve blood transfusion independence and remain transfusion free.

"These landmark data demonstrate that Revlimid, in many cases, eliminates all signs of the cancers genetic cause, on partial deletion of chromosome 5, and as a consequence reduce or even eliminate the need for transfusions in many patients with MDS. After over two years of follow up, these responses have sustained," said List, Professor of Oncology and Medicine and Chief, Division of Hematology Malignancies at Moffitt, and lead investigator of the study. "It is very rewarding to see patients treated with Revlimid, living longer, living three or four years transfusion free and having a better quality of life overall."

MDS, a cancer in which the bone marrow fails to make enough functioning blood cells, affects 300,000 people worldwide killing 60,000 to 70,000 a year. MDS patients suffer from anemia and fatigue and need whole-body blood transfusions as much as twice a month. Repeated transfusions can lead to a toxic buildup called "iron overload" that severely damages the heart, liver and pancreas, and patients eventually succumb to the disease.

The data presented by List showed that two-thirds of patients who received Revlimid were completely freed from the need for blood transfusions. More significantly, in 44 percent of patients, there was no detectable trace of the cancer and after two years of follow-up the median duration has not yet been achieved.

Additional data o
'"/>


11-Dec-2006


Page: 1 2

Related biology news :

1. After a decades-long search, scientists identify new genetic risk factors for multiple sclerosis
2. After scrutiny, preemie lung treatments turn out to be safe, effective
3. After North Korea test, what can be done to reduce the growing nuclear threat?
4. After insects attack, plants bunker sugars for later regrowth
5. After the Hurricanes
6. After the yeast is gone bacteria continue to develop flavor of sparkling wine
7. After a time-shift, mixed signals from the circadian clock
8. After flu exposure, mild exercise protects mature mice from dying
9. Allergy battle could be won in five years, says scientist
10. New study warns limited carbon market puts 20 percent of tropical forest at risk
11. Clones on task serve greater good, evolutionary study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/13/2020)... ... March 13, 2020 , ... According to the American Academy ... and possibly be transmitted by aerosol or direct contact with the conjunctiva, the ... special precautions to avoid contracting the coronavirus. Touching the eyes while inserting contact ...
(Date:3/11/2020)... SANTA CLARA, Calif. (PRWEB) , ... March 11, ... ... in IoT solutions for wireless sensing, today announced smart human body temperature infrared ... big data based self-calibrated thermal meter WxS x800-IRTM, supporting flexible wireless uplink for ...
(Date:3/5/2020)... ... March 05, 2020 , ... With numerous products in ... GmbH to accelerate Cytonus’ existing products and to expand the companies’ intellectual property ... a biotech company located in Austria. , Phoenestra has developed IP assets ...
Breaking Biology News(10 mins):
(Date:3/12/2020)... ... March 12, 2020 , ... ... microscopy (AFM) technology, increases the business investment in Europe by inaugurating a new ... Grand Opening Ceremony of the new Nanoscience Center Europe took place Tuesday, February ...
(Date:3/10/2020)... ... March 10, 2020 , ... ... pleased to announce the addition of Carson Dickey to its growing engineering ... in the biopharmaceutical cold chain. He provides design and validation engineering services ...
(Date:3/4/2020)... ... March 04, 2020 , ... ... provider of recombinant antibody products and services, today announced the launch of ... to rapidly express a large number of antibodies at 80 ml scale. ...
(Date:3/3/2020)... ... March 03, 2020 , ... ... biotech and medical device industries, was recognized by INC. 5,000 on an annual ... lists to note industry leaders greatly impacting their spheres of influence and experiencing ...
Breaking Biology Technology:
Cached News: